"Inhibition of indole-amine 2,3 dioxygenase to enhance ovarian tumor immunity"
Co-Leaders: Kunle Odunsi, MD, PhD; Protul Shrikant, PhD
This project will test a novel therapeutic strategy to break indoleamine 2,3-dioxygenase (IDO)-mediated immune tolerance in ovarian cancer, while inducing anti-tumor-specific immunity in ovarian cancer patients in second remission.
“Rapamycin and IL-21 conditioned CD8+ T cells for adoptive cellular therapy of ovarian cancer”
Co-Leaders: Cassian Yee, MD, PhD; Protul Shrikant, PhD; Kunle Odunsi, MD, PhD
This project will test a combinatorial strategy of mTOR inhibiton and IL-21 for ex-vivo conditioning of antigen stimulated CD8+ T cells for effector and memory functional attributes; and test whether the ex-vivo generated cells produce durable immunity against ovarian tumors in a clinical trial.
This project will test whether autologous tumor-loaded type-1-polarized dendritic cells (αDC1s) will generate CTLs capable of recognizing ovarian cancer in either MHC class I-restricted-or MHC class I-unrestricted fashion; when used both as a vaccine and for adoptive T cell therapy.
This project will determine the predictive significance of myeloid derived suppressor cells (MDSCs), which have strong immunosuppressive properties in the long-term survival of ovarian cancer patients.